[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100358895":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":14,"locations":23,"responsibleParty":41,"collaborators":43,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":7,"studyType":62,"phases":7,"briefSummary":63,"conditions":64,"keywords":69,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"University of Calgary","OTHER",null,[9,12],{"name":10,"affiliation":5,"role":11},"Chad Bousman, PhD","PRINCIPAL_INVESTIGATOR",{"name":13,"affiliation":5,"role":11},"Paul Arnold, MD",[15,20],{"name":16,"role":17,"phone":18,"phoneExt":7,"email":19},"Madison Heintz, MSW","CONTACT","5875739747","psychpgxlab@ucalgary.ca",{"name":21,"role":17,"phone":7,"phoneExt":7,"email":22},"Abdullah Al Maruf, PhD","abdullahal.maruf@ucalgary.ca",[24],{"facility":25,"status":26,"city":27,"state":28,"zip":7,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Child and Adolescent Addiction, Mental Health & Psychiatry","RECRUITING","Calgary","Alberta","Canada","CA",{"type":32,"coordinates":33},"Point",[34,35],-114.08529,51.05011,{"lat":35,"lon":34},[38,39,40],{"name":16,"role":17,"phone":7,"phoneExt":7,"email":7},{"name":10,"role":11,"phone":7,"phoneExt":7,"email":7},{"name":13,"role":11,"phone":7,"phoneExt":7,"email":7},{"type":42,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[44,46],{"name":45,"class":6},"Hotchkiss Brain Institute, University of Calgary",{"name":47,"class":6},"Alberta Health services","100358895","pharmacogenetics-of-antidepressant-induced-disinhibition-100358895",false,"NCT03953014","Pharmacogenetics of Antidepressant-Induced Disinhibition","Pharmacogenetics of Antidepressant-Induced Disinhibition in Children Study","PGx-AID","Inclusion Criteria:\n\n1. Aged 6 - 24 years\n2. Medical records available\n3. Diagnosis of MDD, anxiety disorder, or OCD\n4. Current or past history of SSRI therapy\n\nExclusion Criteria:\n\n1. Inability of parent\u002Flegal guardian to give informed consent\n2. Inability of the child to give informed assent\n3. Unwillingness of child to provide saliva sample for genetic analysis\n4. Current, past or suspected diagnosis of attention deficit hyperactivity disorder, oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, or pervasive developmental disorder.","ALL","6 Years","17 Years",{"count":60,"type":61},120,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to identify pharmacogenetic profiles associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioral disinhibition in children with Major depressive disorder (MDD), anxiety disorders and\u002For obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.",[65,66,67,68],"Obsessive-Compulsive Disorder","Anxiety Disorders","Major Depressive Disorder","Antidepressant Drug Adverse Reaction",[70,71,72,73,74,75],"SSRI","Depression","Children","OCD","Anxiety","Antidepressants","2026-05-11",{"date":78,"type":79},"2026-05-14","ACTUAL",{"date":81,"type":79},"2019-01-02",{"date":83,"type":61},"2026-12-30",{"name":5,"class":6},1]